Abstract
Influenza virus infections in high risk individuals, such as infants, the elderly, and patients with cardiopulmonary disorders or immunocompromised states, cause severe manifestations which often result in fatalities. The emergence of a new antigen type of influenza A virus (H5N1) in Hong Kong during 1997 and 1998 threatened a possible pandemic of a new influenza infection.
The investigation for anti-influenza chemotherapies has progressed in the last decade whereas clinical trials of new compounds have been limited to amantadine, rimantadine and ribavirin. Fusion inhibitors which directly inhibit conformational change of haemagglutinin (HA), protease inhibitors which inhibit cleavage of HA to HA1 and HA2, RNA transcription inhibitors which inhibit cap formation of mRNA and antisense oligonucleotides targeted at mRNA of PB2 (a part of viral RNA polymerase) have been reported, in their development phases.
Recently, 2 neuraminidase (NA) inhibitors, zanamivir and oseltamivir (GS 4104), were used in clinical trials for the treatment of patients with influenza. Both agents showed promising results. A polyoxometalate, PM-523, inhibits fusion between the virus envelope and cell membrane and inhibits the penetration of the virus into cells. This compound has shown potent anti-influenza activity and synergistic inhibitory activity in combination with ribavirin or zanamivir in vitro and in vivo.
Resistant strains for zanamivir, oseltamivir or PM-523 have been isolated. The analysis of mutation points of these strains have contributed to the investigation of the antiviral mechanisms of action of these compounds and the mechanism of resistance of the mutants to these compounds.
Article PDF
Similar content being viewed by others
References
Togashi T. Influenza in children [in Japanese]. J Jpn Med Assoc 1998; 12: 1038–43
Health and Welfare Statistics Association. Jpn J Health Welfare Stat 1998; 45: 414–5
Subbara BK, Klimov A, Katz J, et al. Characterization of an avian A(H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998; 279: 393–6
Claas EC, Osterhaus AD, van Beek R, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998; 351: 472–7
Influenza A (H9N2) in Hong Kong special administrative region of China (SAR). Communicable Disease Surveillance and Response (CRS) [online]. 1999 April 7. Available from: URL: http://www.who.org/emc/outbreak_news [Accessed 1999 Sep 13]
Stewart-Harris CH, Shield GC. Influenza: the virus and disease. London: Edward Arnold, 1976
Kaji M. What is ‘cold syndrome’ [in Japanese]. Rinshou Kenkyu 1996; 73: 2677–81
Jackson GG, Muldoon RL, Akers LW. Serological evidence for prevention of influenzal infection in volunteers by antiinfluenzal drug adamantanamine hydrochloride. Antimicrob Agents Chemother 1963; 3: 703–7
Isunoda A, Massah HF, Cochran KW, et al. Antiviral activity of alpha-1-adamantanemethylamine hydrochloride. Antimicrob Agents Chemother 1965; 5: 553–60
Monto AS, Ohmit SE, Hornbuckle K, et al. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 1995; 39: 2224–8
Dolin R, Richman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine In the prophylaxis of Influenza A Infection. N Engl J Med 1982; 307: 580–3
Belshe RB, Burk B, Newman F, et al. Resistance of influenza Avirus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989; 159: 430–5
Gilbert BE, Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother 1986; 30: 201–5
Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991; 325: 24–9
Stein DS, Creticos CM, Jackson GG, et al. Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother 1987; 31: 1285–7
Hayden FG, Sable CA, Connor JD, et al. Intravenous ribavirin by constant infusion for serious influenza and parinfluenza-virus infection. Antiviral Ther 1996; 1: 51–6
Luo G, Torri A, Harte WE, et al. Molecular mechanism underlying action of a novel fusion inhibitor of influenza A virus. J Virol 1997; 71: 4062–70
Hosoya M, Matsuyama S, Baba M, et al. Effects of protease inhibitors on replication of various myxoviruses. Antimicrob Agents Chemother 1992; 36: 1432–6
Hosoya M, Shigeta S, Ishii T, et al. Comparative inhibitory effects of various nucleoside analogues on replication of influenza virus types A and B in vitro and in vivo. J Infect Dis 1993; 168: 641–6
Tomassini J, Selnick H, Davies ME, et al. Inhibition of Cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2, 4-dioxobutanoic acid compounds. Antimicrob Agents Chemother 1994; 38; 2827–37
Cianci C, Chung TDY, Meanwell N, et al. Identification of N-hydroxamic acid and N-hydroxyimide compounds that inhibit the influenza virus polymerase. Antiviral Chem Chemother 1996; 7: 353–60
Abe T, Suzuki S, Hatta T, et al. Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells. Antiviral Chem Chemother 1998; 9: 253–62
Miztu T, Fujiwara M, Hatta T, et al. Antisense oligonuleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. Nature Biotechnology 1999; 17: 583–7
Barnard DL, Hill CL, Gage T, et al. Potent inhibition of respiratory syncytial virus by polyoxo-metalates of several structural classes. Antiviral Res 1997; 34: 27–37
Huffman JH, Sidwell RW, Barnard DL, et al. Influenza virus inhibitory effects of a series of germanium- and silicon-centred polyoxometalates. Antiviral Chem Chemother 1997; 8: 75–83
Shigeta S, Mori S, Watanabe J, et al. In vitro antimyxovirus activity and mechanism of anti-influenza virus activity of polyoxometalates PM-504 and PM-523. Antiviral Chem Chemother 1996; 7: 346–52
Shigeta S, Mori S, Watanabe J, et al. Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo. Antimicrob Agents Chemother 1997; 41: 1423–7
Chou TC. Quantitation dose-effect analysis and algorithms. A theoretical study. Asia Pac J Pharmacol 1987; 2: 93–9
Chou J, Chou TC. Dose-effect analysis with microcomputers. Cambridge: Biosoft, 1987: 33–56
von Itzstein M, Wu W-Y, Kok GB, et al. Rational Design of potent sialidase-based inhibitors of influenza replication. Nature 1993; 363: 418–23
Hayden FG, Osterhaus A, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337: 874–80
Silagy CA, the MIST study group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877–81
Gubareva LV, Robinson MJ, Bethell RC, et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71: 3385–90
Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178: 1257–62
Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of neuraminidase inhibitor zanamivir in the treatment of influenza A and B infections. J Infect Dis 1999; 180: 254–61
Eisenberg EJ, Bidgood A, Cundy C. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4014. Antimicrob Agents Chemother 1997; 41: 1949–52
Sidwell RW, Huffman JH, Barnard DL, et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza neuraminidase inhibitor. Antiviral Res 1998; 37: 107–20
Hayden FG, Lobo M, Treanor JJ. Efficacy and tolerability of oral GS4104 for early treatment of experimental influenza in humans [abstract]. 37th Internscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 14
Aoki F, Osterhaus A, Rimmelzwaan G, et al. Oral GS4104 successfully reduced duration and severity of naturally acquired influenza [abstract]. 38th Internscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego (CA), 22
Mendel DB, Sidwell RW. Influenza virus resistance to neuraminidase inhibitors. Drug Resist Updates 1998; 1: 184–9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shigeta, S. Recent Progress in Anti-Influenza Chemotherapy. Drugs R&D 2, 153–164 (1999). https://doi.org/10.2165/00126839-199902030-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902030-00001